Idenix Pharmaceuticals (IDIX)

[DewDiligence]

IDIX’s 2008 Clinical Goals

[Updated re IDX899.]

HIV

--Complete phase-1/2 IDX899 7-day monotherapy study. Data from the 800mg cohort were reported on 2/6/08: #msg-26606685.

--Start phase-2 IDX899 6-week combination study; this will be a head-to-head trial of IDX899+Truvada vs Sustiva+Truvada in first- or second-line patients.

--Partner IDX899 program following phase-2 study.

HCV

--File IND for the nucleotide prodrug, IDX184, and complete phase-1 trial.

--Start phase-2a study for IDX184 in combination with HCV SoC.

--File IND for HCV protease inhibitor and complete phase-1 trial.